The biotech IPO window is officially open.
Eleven second-quarter biotech initial public offerings totaling $1 billion — the strongest quarterly biotech market for venture-backed IPOs since third-quarter 2000 — fueled an overall surge in IPOs, according to the National Venture Capital Association and news and data company Thomson Reuters.
{iframe}http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/07/ipo-ma-nvca-venture-capital.html?page=all{/iframe}